UAE’s Mubadala Capital, Qatari QIA Lead Iambic Therapeutics’ Series B Funding
23/06/2024 06:42 GMT

Iambic Therapeutics, a US-based clinical-stage biotechnology company, has raised US$50 million in Series B extension funding led by the UAE’s Mubadala Capital, the wholly owned subsidiary of Mubadala... More


More Qatar News